GLPwatch
Papers (10588)
Page 162 of 177, ranked by citation count.
- GLP-1 receptor agonists and their role in managing type 2 diabetes.
- Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.
- Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".
- Response by Wiberg et al to Letter Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.
- Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension.
- Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2.
- Estimation of Interventional Effects in Clinical Trials With a Repeatedly Measured Mediator.
- [Exenatide promotes cholesterol efflux in pancreatic tissue of obese diabetic rats].
- Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.
- Do GLP-1 receptor agonists improve insulin sensitivity and reduce lipid accumulation in skeletal muscles and the liver independent of weight loss?
- [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
- Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
- Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.
- Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
- From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.
- N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
- [Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].
- Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived β cells during transplantation.
- Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.
- Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
- GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.
- Tirzepatide: A promising treatment for obesity?
- Liraglutide therapy in an adolescent with Prader‑Willi syndrome and concomitant diabetes mellitus.
- Semaglutide (Wegovy) for MASH.
- A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications.
- Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.
- Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
- [Therapeutic use and adverse events of incretin-related drugs].
- Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
- Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
- AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
- Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.
- [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
- [Obesity: novel pharmacological treatments].
- Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.
- Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide.
- Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.
- Current clinical application of incretin therapy for obesity management.
- Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.
- Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
- A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.
- Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
- FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.
- Difficult to defeat obesity: An 8D approach.
- Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.
- Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
- Hormone copycats.
- Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.
- Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.
- GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
- Semaglutide (Wegovy) for weight loss.
- Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
- PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.
- A cardiovascular indication for oral semaglutide (Rybelsus).